alpha-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response
AffiliationRobert W Franz Cancer Research Center, Earle A Chiles Research Institute, Providence Portland Medical Center, 4805 NE Glisan Street, Portland, OR 97213, USA
Department of Chemistry and Biochemistry, University of Arizona, 1306 East University Boulevard, Tucson, AZ 85721, USA
MetadataShow full item record
CitationHahn et al. Breast Cancer Research 2011, 13:R4 http://breast-cancer-research.com/content/13/1/R4
JournalBreast Cancer Research
Rights© 2011 Hahn et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0)
Collection InformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at firstname.lastname@example.org.
AbstractINTRODUCTION:alpha-Tocopheryloxyacetic acid (alpha-TEA) is a novel ether derivative of alpha-tocopherol that has generated interest as a chemotherapeutic agent because of its selective toxicity toward tumor cells and its ability to suppress tumor growth in various rodent and human xenograft models. We previously reported that oral alpha-TEA inhibited the growth of both a transplanted (4T1) and a spontaneous MMTV-PyMT mouse model of breast cancer.METHODS:Because little is known about the possible immunological mechanisms underlying the in vivo alpha-TEA effects, we evaluated the impact of alpha-TEA therapy on the immune response by characterizing immune cell populations infiltrating the tumor site.RESULTS:alpha-TEA treatment resulted in higher frequencies of activated T cells in the tumor microenvironment and twofold and sixfold higher ratios of CD4+ and CD8+ T cells to regulatory T cells, respectively. This finding was correlated with an increased ability of tumor-draining lymph node cells and splenocytes from alpha-TEA-treated mice to secrete interferon (IFN)-gamma in response to CD3 or to mediate a cytolytic response in a tumor-specific fashion, respectively. That the alpha-TEA-mediated antitumor effect had a T cell-dependent component was demonstrated by the partial abrogation of tumor suppression when CD4+ and CD8+ T cells were depleted. We also determined the intratumoral cytokine and chemokine profile and found that alpha-TEA treatment increased intratumoral IFN-gamma levels but decreased interleukin (IL)-4 levels, suggesting a shift toward a TH1 response. In addition, alpha-TEA induced higher levels of the inflammatory cytokine IL-6 and the chemokine CCL5.CONCLUSIONS:Taken together, these data suggest that alpha-TEA treatment, in addition to its direct cytotoxic effects, enhanced the anti-tumor immune response. This study provides a better understanding of the mechanisms of action of alpha-TEA and its effect on the immune system and may prove useful in designing immune-stimulating strategies to boost the antitumor effects of alpha-TEA in breast cancer patients.
VersionFinal published version